Journal Article

Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

  • Gong J
  • Mita A
  • Wei Z
  • et al.
JCO Precision Oncology (2024) (8)
DOI: 10.1200/po.23.00406
20Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Limited activity of FGFR inhibition in solid tumors with FGFR amplifications in this NCI-MATCH phase II trial.

Cite

CITATION STYLE

APA

Gong, J., Mita, A. C., Wei, Z., Cheng, H. H., Mitchell, E. P., Wright, J. J., … Flaherty, K. T. (2024). Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1. JCO Precision Oncology, (8). https://doi.org/10.1200/po.23.00406

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free